ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer

Although EZH2 enzymatic inhibitors have shown anti-tumor effects in EZH2-mutated lymphoma and ARID1A-mutated ovarian cancer, many cancers do not respond because EZH2 can promote cancer independently of its histone methyltransferase activity. Here we identify ZRANB1 as the EZH2 deubiquitinase. ZRANB1...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Rep
Main Authors: Zhang, Peijing, Xiao, Zhenna, Wang, Shouyu, Zhang, Mutian, Wei, Yongkun, Hang, Qinglei, Kim, Jongchan, Yao, Fan, Rodriguez-Aguayo, Cristian, Ton, Baochau N., Lee, Minjung, Wang, Yumeng, Zhou, Zhicheng, Zeng, Liyong, Hu, Xiaoyu, Lawhon, Sarah E., Siverly, Ashley N., Su, Xiaohua, Li, Jia, Xie, Xiaoping, Cheng, Xuhong, Liu, Liang-Chiu, Chang, Hui-Wen, Chiang, Shu-Fen, Lopez-Berestein, Gabriel, Sood, Anil K., Chen, Junjie, You, M. James, Sun, Shao-Cong, Liang, Han, Huang, Yun, Yang, Xianbin, Sun, Deqiang, Sun, Yutong, Hung, Mien-Chie, Ma, Li
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5933875/
https://ncbi.nlm.nih.gov/pubmed/29669287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2018.03.078
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados